DeepTech for longevity and mental health

Engineered fungi that make new molecules for the mind.

We use AI and synthetic biology to design non-psychedelic neuroplastogens: compounds built to help the brain rebuild its own connections.

The brain knows how to repair itself. It only lacks the right signal. We found that signal underground.

Three networks.
One shape.

  1. The sign

    The “o” of æon is a ring of nodes around an active centre: a molecule and a network at once, with no beginning and no end.

  2. Mycelium

    Underground, ancestral, alive. Fungi have spent millions of years evolving chemistry that talks to other living systems.

  3. Neurons

    Neuroplasticity: the mind can reconfigure itself. Our molecules are designed to support that capacity rather than mask symptoms.

  4. Cosmos

    Orbits, trajectories, deep time. Aeon means an age without measure, and longevity is the question we care about most.

Living longer is not the same as living well.

Global average at birth. Each dot is one year of life.
Healthy life expectancy
62.8 years
Years in poor health
10.5 years

74%

of all deaths are now due to chronic diseases, up from 58% in 2000.

57M

people live with dementia. Deaths have tripled since 2000.

1B+

people live with a mental disorder, including 332 million with depression.

2.1B

people will be aged 60 or over by 2050, 22% of the world’s population.

Pharma has managed the mind for fifty years. It hasn’t healed it.

1 in 3 patients reach remission on antidepressants.

1 in 2 chronic patients experience withdrawal.

1 in 4 users have taken antidepressants for 10+ years.

Sources: WHO Global Health Estimates; WHO Dementia, Mental Health and Ageing fact sheets; UN World Population Prospects 2024; IHME GBD 2023; STAR*D, Rush et al., Am J Psychiatry 2006; Davies & Read, Addictive Behaviors 2019; CDC NCHS Data Brief 283.

Heal the mind at its source.

Engineered fungi produce biosynthetic neuroplastogens. Our lead program targets a single switch in the brain’s own repair system.

æon neuro+the molecule
TrkB receptorone switch
BDNFneuroplasticity
  • Neuroregeneration

    Designed to help rebuild lost connections.

  • Neurogenesis

    Supporting new neurons in the hippocampus.

  • Neuroprotection

    Shielding neurons from cell death.

  • Cognitive wellness

    Memory, learning, focus and mood.

The brain-repair promise studied in psychedelic research, designed without the psychedelic experience.

Bioluminescent pink fungi on a dark background

AI + engineered fungi = new molecules.

One R&D pipeline, from data to molecule. Each stage feeds the next.

  1. 01 Design

    MYCENAIA engine

    Our AI platform discovers and designs bioactive compounds and biosynthetic routes from omics data.

  2. 02 Build

    Fungal biofactories

    Genetic engineering and CRISPR/Cas9 to build biosynthetic pathways and high-yield producer strains.

  3. 03 Deliver

    Tailored molecules

    Compounds for mood modulation, longevity and healthspan, produced by fermentation.

Program 01 · 2026–2028

5-OH-indole derivatives

Non-psychedelic TrkB agonists, designed for a nutraceutical first path through FDA new dietary ingredient (NDI) notification, with pharmaceutical applications to follow through partnerships.

IP-first. Asset-light. B2B.

  1. Protect

    Global IP

    Producer strains, bioprocesses and novel molecules, filed through USPTO, PCT and EPO.

  2. Regulate

    FDA notification

    NDI notification first. Pharmaceutical development later, as a separate API through partners.

  3. Produce

    Certified CDMOs

    R&D in Chile. Scale-up in the United States with cGMP-certified manufacturing partners.

  4. Sell

    B2B off-take

    Ingredients for nutraceutical brands now; high-purity molecules for pharma partners later.

From engineered strain to FDA filing.

Each step de-risks the next.

  1. 2026 Build

    • R&D team running at Merken Biotech labs
    • Alliances with CROs, CDMOs and buyers

    We are here

  2. 2027 Prove

    • First Program 01 molecules
    • Provisional patent at the USPTO
    • Validation and pre-clinical studies
  3. 2028 Launch

    • NDI notification submitted to the FDA
    • USPTO, PCT and EPO applications
    • Asset-light production and go-to-market

team → molecules → IP → FDA notification → production → B2B

Deep science, proven operators.

Core team

  • Leopoldo Naranjo, Ph.D.

    Founder & CSO. Genetic engineering of fungi.

  • Felipe Muñoz, Ph.D.

    Head of Strain Engineering. IBIO, UC.

  • Valentina Hernández

    R&D Biochemist. USACH.

Board of Directors

  • Javier Guerrero, Ph.D.

    Board member. CEO of Merken Biotech and CEO of Praxis Bio.

Advisors

  • Christopher Timmermann, Ph.D.

    Neuroscience. Imperial College London.

  • Renato Chávez, Ph.D.

    Fungal genetics. USACH.

  • David Alvo, M.Sc.

    Fundraising strategy. Impacta VC.

  • Diego Velázquez, M.Sc.

    AI and software, MYCENAIA. UNAM.

R&D alliances

Merken Biotech and Praxis Bio, two of Chile’s most experienced drug-validation companies: seven Ph.D.s with more than sixteen years of experience.

Build the next molecule with us.

We work with CDMOs, CROs, ingredient buyers, research partners and investors who share our standard: if it can’t be traced to a paper or a strain, we don’t say it.

Email lnaranjo@aeon-deep.tech